9:04 AM Abstract No. 67 - Longitudinal quality of life assessment of patients with hepatic metastatic colorectal adenocarcinoma after treatment with transarterial radioembolization Yttrium-90 therapy

Abstract

Purpose To determine the effects of transarterial radioembolization therapy with Y-90 on health-related quality of life (HRQOL) of patients with hepatic metastatic colorectal adenocarcinoma. Materials and Methods Single-center, IRB-approved, prospective health-related quality of life study with analysis of the Short-Form 36 (SF-36) assessment tool, before and after Y-90 radioembolization was performed. Patient age ranged from 44-83 years with a mean of 60.15 years. Baseline HRQOL scores were evaluated for significant (P Results Patients had increased pretreatment baseline scores within all categories except, vitality, compared to age-adjusted norms. After treatment bodily pain (52.42 vs 48.41), social function (62.50 vs 49.93), role-emotional (59.72 vs 49.79), and mental health (71.67 vs 51.25) parameters remained increased compared to age-adjusted norms. All parameters decreased from pre-treatment compared to post-treatment, however, only social functioning (score change, -20.5; P=.049), and general health (score change, -15.2; P=.022) parameters were statistically significant. Results of the surveys were analyzed utilizing a two sample t-test for each comparison. Conclusion Generally, patients with hepatic metastatic colorectal cancer treated with Y-90 radioembolization negatively perceive, decreased health related quality of life after treatment compared with pre-treatment. However, only Social functioning and general health parameters are statistically significant (p